Karyopharm Therapeutics, Inc. (KPTI)
1.86
-0.10
(-5.10%)
USD |
NASDAQ |
Aug 24, 16:00
1.87
+0.01
(+0.54%)
After-Hours: 20:00
Karyopharm Therapeutics Gross Profit Margin (Quarterly) : 96.75% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 96.75% |
| March 31, 2026 | 96.13% |
| December 31, 2025 | 95.59% |
| September 30, 2025 | 94.93% |
| June 30, 2025 | 97.02% |
| March 31, 2025 | 95.41% |
| December 31, 2024 | 95.38% |
| September 30, 2024 | 96.43% |
| June 30, 2024 | 96.36% |
| March 31, 2024 | 93.97% |
| December 31, 2023 | 95.37% |
| September 30, 2023 | 97.25% |
| June 30, 2023 | 96.60% |
| March 31, 2023 | 95.76% |
| December 31, 2022 | 94.10% |
| September 30, 2022 | 96.79% |
| June 30, 2022 | 97.26% |
| March 31, 2022 | 96.64% |
| December 31, 2021 | 99.30% |
| September 30, 2021 | 97.94% |
| June 30, 2021 | 93.95% |
| March 31, 2021 | 94.98% |
| December 31, 2020 | 96.27% |
| September 30, 2020 | 96.85% |
| June 30, 2020 | 98.11% |
| Date | Value |
|---|---|
| March 31, 2020 | 94.15% |
| December 31, 2019 | 90.95% |
| September 30, 2019 | 90.45% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Madrigal Pharmaceuticals, Inc. | 88.91% |
| Relay Therapeutics, Inc. | -2.86% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -200.2% |
| Profit Margin (Quarterly) | -200.5% |
| Operating Margin (Quarterly) | -67.38% |
| Return on Net Operating Assets | -596.3% |